Association of serum fetuin-A with valvular calcium concentration in rheumatic mitral valve disease

Journal of Heart Valve Disease

Volumn 19, Issue 5, 2010, Pages 636-643

  Cagli, Kumral ^a   Basar, Nurcan ^a   Cagli, Kerim ^a   Armutcu, Ferah ^b   Aylak, Firdevs ^c   Yalcinkaya, Adnan ^a   Erden, Gonul ^d   Kadirogullari, Ersin ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b FATIH UNIVERSITY   (Turkey)

^c SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; FETUIN A; PHOSPHORUS;

ADULT; ARTICLE; BLOOD LEVEL; CALCIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART VALVE REPLACEMENT; HUMAN; MALE; MITRAL VALVE; MITRAL VALVE DISEASE; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; C-REACTIVE PROTEIN; CALCINOSIS; CALCIUM; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; PHOSPHORUS; RHEUMATIC HEART DISEASE;

EID: 78149254371     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. J Biol Chem 1999;274:28514-28520
2. Szweras M, Liu D, Partridge EA, et al. Alpha 2-HS glycoprotein/feruin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002;277:19991-19997
3. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366
4. Heiss A, DuChesne A, Denecke B, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003;278:13333-13341
5. Price PA, Lim JE. The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 2003;278:22144-22152
6. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 2003;361:827-833
7. Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920-2930
8. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteier M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: Data from the Heart and Soul Study. Circulation 2006;113:1760-1767
9. Rajamannan NM, Nealis TB, Subramaniam M, et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005;111:3296-3301
10. Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007;171:1407-1418
11. Mathieu P, Voisine P, Pépin A, Shetty R, Savard N, Dagenais F. Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity. J Heart Valve Dis 2005;14:353-357
12. Mohler ER, III, Chawla MK, Chang AW, et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999;8:254-260
13. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 2007;115:2533-2539
14. Kaden JJ, Reinöhl JO, Blesch B, et al. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med 2007;20:193-197
15. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:167-184
16. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: An analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60:299-308
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
18. Vural H, Uzun E, Uz E, Kocyigit A, Cigli A, Akyol O. Concentration of copper, zinc and various elements in serum of patients with bronchial asthma. J Trace Elements Med Biol 2000;14:88-91
19. Merx MW, Schäfer C, Westenfeld R, et al. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 2005;16:3357-3364
20. Keeley FW, Sitarz EE. Identification and quantitation of alpha 2-HS-glycoprotein in the mineralized matrix of calcified plaques of atherosclerotic human aorta. Atherosclerosis 1985;55:63-69
21. Kazama JJ, Gejyo F, Ei I. The immunohistochemical localization of alpha2-Heremans-Schmid glycoprotein/fetuin-A (AHSG). Nephrol Dial Transplant 2005;20:851-852
22. Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:1676-1685
23. Gölbasi Z, Uçar O, Keles T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: Evidence of ongoing inflammation. Eur J Heart Fail 2002;4:593-595
24. Davutoglu V, Celik A, Aksoy M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 2005;14:251-256
25. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: Evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-1129
26. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-2392
27. Gangneux C, Daveau M, Hiron M, Derambure C, Papaconstantinou J, Salier JP. The inflammation-induced down-regulation of plasma Fetuin-A (alpha2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites. Nucleic Acids Res 2003;31:5957-5970
28. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767
29. Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 2008;3:e1765
30. Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996;271:12755-12761
31. Ombrellino M, Wang H, Yang H, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to car- rageenan. Shock 2001;15:181-185
32. Tohno Y, Tohno S, Satoh H, et al. Compositional changes of human mitral valves with aging. Biol Trace Element Res 2002;88:203-213
33. Maxwell L, Gavin JB, Barratt-Boyes BG. Differences between heart valve allografts and xenografts in the incidence and initiation of dystrophic calcification. Pathology 1989;21:5-10
34. Atalar E, Ozturk E, Ozer N, et al. Plasma soluble osteopontin concentrations are increased in patients with rheumatic mitral stenosis and associated with the severity of mitral valve calcium. Am J Cardiol 2006;98:817-820